Abstract:Developing novel substances to synergize with nanozymes is a challenging yet indispensable task to enable the nanozyme-based therapeutics to tackle individual variations in tumor physicochemical properties. The advancement of machine learning (ML) has provided a useful tool to enhance the accuracy and efficiency in developing synergistic substances. In this study, ML models to mine low-cytotoxicity oncolytic peptides are applied. The filtering Pipeline is constructed using a traversal design and the Autogluon framework. Through the Pipeline, 37 novel peptides with high oncolytic activity against cancer cells and low cytotoxicity to normal cells are identified from a library of 25,740 sequences. Combining dataset testing with cytotoxicity experiments, an 80% accuracy rate is achieved, verifying the reliability of ML predictions. Peptide C2 is proven to possess membranolytic functions specifically for tumor cells as targeted by Pipeline. Then Peptide C2 with CoFe hollow hydroxide nanozyme (H-CF) to form the peptide/H-CF composite is integrated. The new composite exhibited acid-triggered membranolytic function and potent peroxidase-like (POD-like) activity, which induce ferroptosis to tumor cells and inhibits tumor growth. The study suggests that this novel ML-assisted design approach can offer an accurate and efficient paradigm for developing both oncolytic peptides and synergistic peptides for catalytic materials. Using the stretching-induced crystallization of natural rubber and the hydrogen bond rearrangement of the polyvinyl alcohol network, a muscle bionic shape memory hydrogel with a multiscale oriented structure is prepared. This strategy provides a new idea for the toughening and high performance of shape memory hydrogels.image

Three Rounds of Stability-Guided Optimization and Systematical Evaluation of Oncolytic Peptide LTX-315

Synthesis and structural optimization of oncolytic peptide LTX-315

Design, Synthesis and Biological Evaluation of Novel Tripeptidyl Epoxyketone Derivatives Constructed from Β-Amino Acid As Proteasome Inhibitors.

Efficient synthesis and anticancer evaluation of spider toxin peptide LVTX-8-based analogues with enhanced stability

Oncolytic Immunotherapy: Multiple Mechanisms of Oncolytic Peptides to Confer Anticancer Immunity

Design, Synthesis, and Biological Evaluation of Novel Phenol Ether Derivatives As Non-Covalent Proteasome Inhibitors.

Design, Synthesis and Biological Evaluation of Novel Non-peptide Boronic Acid Derivatives As Proteasome Inhibitors

A Modified HLA-A*0201-restricted CTL Epitope from Human Oncoprotein (hpebp4) Induces More Efficient Antitumor Responses

Rational design of a new short anticancer peptide with good potential for cancer treatment

Oncolytic Peptide-Nanoplatform Drives Oncoimmune Response and Reverses Adenosine-Induced Immunosuppressive Tumor Microenvironment

Development of a Lytic Peptide Derived from BH3-only Proteins

From oncolytic peptides to oncolytic polymers: A new paradigm for oncotherapy

Stapled Wasp Venom-Derived Oncolytic Peptides with Side Chains Induce Rapid Membrane Lysis and Prolonged Immune Responses in Melanoma

Hollow CoFe Nanozymes Integrated with Oncolytic Peptides Designed Via Machine-Learning for Tumor Therapy

The Development of Activatable Lytic Peptides for Targeting Triple Negative Breast Cancer

Metabolism guided optimization of peptidomimetics as non-covalent proteasome inhibitors for cancer treatment

Enhancing the Stability of Tumor Homing LyP-1 Peptide Using Cyclization and Retro Grafting Strategies

Engineering Oncolytic Vaccinia Virus with Functional Peptides Through Mild and Universal Strategy

Development of Macrocyclic Peptides Containing Epoxyketone with Oral Availability as Proteasome Inhibitors.

A nano-predator of pathological MDMX construct by clearable supramolecular gold(I)-thiol-peptide complexes achieves safe and potent anti-tumor activity

Design, synthesis and anticancer evaluation of novel oncolytic peptide-chlorambucil conjugates